- インスリン非依存性の、インシュリン非依存性の
WordNet
- used to express refusal or denial or disagreement etc or especially to emphasize a negative statement; "no, you are wrong"
- a negative; "his no was loud and clear"
- referring to the degree to which a certain quality is present; "he was no heavier than a child" (同)no more
- not in any degree or manner; not at all; "he is no better today"
- quantifier; used with either mass nouns or plural count nouns for indicating a complete or almost complete lack or zero quantity of; "we have no bananas"; "no eggs left and no money to buy any"; "have you no decency?"; "did it with no help"; "Ill get you there in no time"
- relying on or requiring a person or thing for support, supply, or what is needed; "dependent children"; "dependent on moisture"
- addicted to a drug (同)dependant, drug-addicted, hooked, strung-out
- contingent on something else (同)dependant, qualified
- (of a clause) unable to stand alone syntactically as a complete sentence; "a subordinate (or dependent) clause functions as a noun or adjective or adverb within a sentence" (同)subordinate
- hormone secreted by the isles of Langerhans in the pancreas; regulates storage of glycogen in the liver and accelerates oxidation of sugar in cells
- the fifth of the seven canonical hours; about 3 p.m.
PrepTutorEJDIC
- 《名詞の前に置いて》『一つも』(『一人も,少しも』)・・・『ない』 / 《補語につけて》『決して・・・でない』 / 《省略文で》・・・なし;・・・お断り / 《話》少ししか(あまり)・・・ない / (肯定の問いに対して)『いいえ』;(否定の問いに対して)はい,ええ / 《not, norの前に挿入して》『いや』,否 / 《形容詞の前に置その形容詞を否定して》…どころではない / 《比較級の前に置いて》ちっとも…でない,…と全く同じ / 《… or no の形で》…であってもなくても / 《驚き・困惑・不信などを表して》とんでもない / 《単数形で》『拒否』,「『いいえ』」という返事 / 《複数形で》反対[投]票
- 『頼っている』,依存している,従属している / 扶養される人(家族)
- インシュリン(膵臓(すいぞう)ホルモンで糖尿病治療剤)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 糖尿病におけるインスリン療法の一般原則general principles of insulin therapy in diabetes mellitus [show details]
- 2. 成人の1型糖尿病における血糖値マネージメントmanagement of blood glucose in adults with type 1 diabetes mellitus [show details]
- 3. 2型糖尿病におけるインスリン療法insulin therapy in type 2 diabetes mellitus [show details]
- 4. 糖尿病における吸入インスリン療法inhaled insulin therapy in diabetes mellitus [show details]
- 5. 糖尿病合併妊娠：妊娠中の血糖コントロールpregestational diabetes mellitus glycemic control during pregnancy [show details]
English Journal
- Myocardial Steatosis and Necrosis in Atria and Ventricles of Rats Given Pyruvate Dehydrogenase Kinase Inhibitors.
- Jones HB1, Reens J, Johnson E, Brocklehurst S, Slater I.Author information 11Pathological Sciences, Global Safety Assessment, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, UK.AbstractPharmaceutical therapies for non-insulin-dependent diabetes mellitus (NIDDM) include plasma glucose lowering by enhancing glucose utilization. The mitochondrial pyruvate dehydrogenase (PDH) complex is important in controlling the balance between glucose and fatty acid substrate oxidation. Administration of pyruvate dehydrogenase kinase inhibitors (PDHKIs) to rats effectively lowers plasma glucose but results in myocardial steatosis that in some instances is associated primarily with atrial and to a lesser degree with ventricular pathology. Induction of myocardial steatosis is not dose-dependent, varies from minimal to moderate severity, and is either of multifocal or diffuse distribution. Ventricular histopathology was restricted to few myocardial degenerative fibers, while that in the atrium/atria was of either acute or chronic appearance with the former showing myocardial degeneration/necrosis, acute myocarditis, edema, endothelial activation (rounding up), endocarditis, and thrombosis associated with moderate myocardial steatosis and the latter with myocardial loss, replacement fibrosis, and no apparent or minimal association with steatosis. The evidence from these evaluations indicate that excessive intramyocardial accumulation of lipid may be either primarily adverse or represents an indicator of other adversely affected cellular processes.
- Toxicologic pathology.Toxicol Pathol.2014 Apr 17. [Epub ahead of print]
- Pharmaceutical therapies for non-insulin-dependent diabetes mellitus (NIDDM) include plasma glucose lowering by enhancing glucose utilization. The mitochondrial pyruvate dehydrogenase (PDH) complex is important in controlling the balance between glucose and fatty acid substrate oxidation. Administra
- PMID 24742628
- On the potential of acarbose to reduce cardiovascular disease.
- Standl E1, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J.Author information 1Munich Diabetes Research Group e,V, at Helmholtz Centre, Ingolstaedter Landstrasse 1, 85764 Munich, Neuherberg, Germany. Eberhard.Standl@lrz.uni-muenchen.de.AbstractIn the emerging landscape of cardiovascular (CV) outcome trials evaluating the effects of blood glucose lowering drugs in individuals with type 2 diabetes, it is becoming increasingly apparent that since the promising signals coming from the United Kingdom Prospective Diabetes Study (UKPDS) no unequivocal benefits have been established for any single therapy thus far. There is an unmet need for introducing an effective pharmacological agent which could target both correlates of glycaemic regulation and CV risk factors, to ameliorate the enormous burden of fatal and non-fatal CV events in diabetic patients. Acarbose, like other alpha-glucosidase inhibitors (AGIs), has been proven to be an effective antidiabetic treatment for decades, but the overall significant impact of this class of drugs on modulating CV risk has only recently been appreciated. Accumulating evidence has shown that apart from its multiple effects on primarily postprandial glucose dysmetabolism, a key component of mechanisms linked to increased incidence of CV events, acarbose therapy also associates with a favorable impact on an array of surrogate markers of CV disease. Data stemming from in vitro testing of human cell lines as well as from preliminary trials in diabetic populations, like the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, have highlighted - though not undisputed - the potential beneficial effects of the drug on CV morbidity. Large scale trials, like the ongoing Acarbose Cardiovascular Evaluation (ACE) trial, aim at conclusively establishing such a positive effect in patients with coronary heart disease and impaired glucose tolerance. In view of its usually acceptable level of side effects that are, if they occur, mostly limited to transient gastrointestinal symptoms, acarbose could well be a strong future player in CV disease secondary prevention. Current discouraging results from many trials of antidiabetic medications to significantly lower CV event rates in diabetic patients, should only draw further attention on alternative glucose lowering agents, among which acarbose is indeed promising.
- Cardiovascular diabetology.Cardiovasc Diabetol.2014 Apr 16;13(1):81. doi: 10.1186/1475-2840-13-81.
- In the emerging landscape of cardiovascular (CV) outcome trials evaluating the effects of blood glucose lowering drugs in individuals with type 2 diabetes, it is becoming increasingly apparent that since the promising signals coming from the United Kingdom Prospective Diabetes Study (UKPDS) no unequ
- PMID 24742256
- Efficacy of pre-exercise low-level laser therapy on isokinetic muscle performance in individuals with type 2 diabetes mellitus: study protocol for a randomized controlled trial.
- Gomes CA1, Leal-Junior EC, Biasotto-Gonzalez DA, El-Hage Y, Politti F, Gonzalez Tde O, Dibai-Filho AV, de Oliveira AR, Frigero M, Antonialli FC, Vanin AA, de Tarso Camillo de Carvalho P.Author information 1Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de Julho (UNINOVE), Av, Dr, Adolfo Pinto, 109, Água Branca, São Paulo, SP 05001-100, Brazil. cid.andre@gmail.com.AbstractBACKGROUND: Type 2 diabetes, also known non-insulin-dependent diabetes, is the most prevalent type of the disease and involves defects in the secretion and action of insulin. The aim of the proposed study is to evaluate the efficacy of pre-exercise low-level laser therapy (LLLT) on muscle performance of the quadriceps femoris in individuals with type 2 diabetes.
- Trials.Trials.2014 Apr 9;15(1):116. doi: 10.1186/1745-6215-15-116.
- BACKGROUND: Type 2 diabetes, also known non-insulin-dependent diabetes, is the most prevalent type of the disease and involves defects in the secretion and action of insulin. The aim of the proposed study is to evaluate the efficacy of pre-exercise low-level laser therapy (LLLT) on muscle performanc
- PMID 24716713
Japanese Journal
- インスリン非依存性糖尿病患者におけるエベロリムス溶出性ステントの優れた成績の可能性 : シロリムス溶出性ステントとの比較
- 荒巻 和彦,山根 正久,入江 寿光 [他]
- 日本心血管インターベンション治療学会誌 5(1), 27-32, 2013-03
- NAID 40019630596
- Preliminary results of pinpoint plantar long-wavelength infrared light irradiation on blood glucose, insulin and stress hormones in patients with type 2 diabetes mellitus
- Ryotokuji Kenji,Ishimaru Keisou,Kihara Kazuhiko,Namiki Yoshihisa,Hozumi Nobumichi
- LASER THERAPY 22(3), 209-214, 2013
- … plantar long-wavelength infrared light irradiation (PP-LILI)", which may be able to relieve mental stress and normalize blood glucose level via the reduction of stress hormones in type 2 (non-insulin-dependent) diabetes mellitus (DM) patients.Materials (Subjects) and methods: Based on this hypothesis, the present study was undertaken to examine effects of PP-LILI on stress hormones (ACTH and cortisol), blood glucose, HbA1c, and insulin levels in 10 patients with type 2 …
- NAID 130004553734
- Slowly Progressive Type 1 Diabetes Treated with Metformin for Five Years after Onset
- Hirata Takumi,Shimada Akira,Morimoto Jiro,Maruyama Taro
- Internal Medicine 52(23), 2635-2637, 2013
- … We expected him to quickly progress to an insulin-dependent state due to a high anti-glutamic acid decarboxylase antibody titer (23.9 U/mL). … At SPIDDM diagnosis, he was in a non-insulin-dependent state, with a fasting serum C-peptide immunoreactivity level of 2.5 ng/mL. … His glycemic control remained stable, and his intrinsic insulin secretion capacity was maintained for five years. …
- NAID 130003383733
Related Links
- Abstract Non-insulin-dependent (type II) diabetes mellitus is an inherited metabolic disorder characterized by hyperglycemia with resistance to ketosis. The onset is usually after age 40 years. Patients are variably ...
- また後者はNIDDM（non-insulin dependent diabetes mellitus）と呼ばれ、おもに2型糖尿病のことを指す言葉として使われていました。実際に、1型糖尿病のほとんどはインスリン依存状態にあり、2型糖尿病の多くはインスリン非依存 « 戻る ...
- The term NID means non insulin dependent. Acknowledgement Dr Helen Dixon a doctor of medicine has proof read this document and found the calculation of equivalent grams of carbohydrate glucose sugar called carb sugar ...
Related Pictures
★リンクテーブル★
| リンク元 | 「noninsulin-dependent」「インスリン非依存性」「インシュリン非依存性」 |
| 拡張検索 | 「non-insulin-dependent diabetes mellitus」 |
| 関連記事 | 「dependent」「n」「non」 |
「noninsulin-dependent」
- インスリン非依存性の、インスリン非依存型の、インシュリン非依存性の
「インスリン非依存性」
「インシュリン非依存性」
「non-insulin-dependent diabetes mellitus」
「dependent」
- adj.
- 依存性の、依存的な、依存型の、依存の
「n」
- n.
- pの前の[n]はmと記載する。synptom→symptom
「non」
- comb form.
- 関
- un